MiMedx Group, Inc. (MDXG) Balance Sheet

Equity dropped from $256.5M to $211.1M over the same period, and the accumulated deficit widened to -$77.1M, which suggests losses are consuming capital faster than it is being replenished. The trend points to a weakening balance sheet trajectory, though the company still carries a substantial equity base relative to its liabilities, so investors should monitor whether the decline stabilizes or accelerates.

The current ratio of 4.35 in 2026Q3 suggests current assets comfortably exceed current liabilities, offering a meaningful short-term buffer. However, given that operating cash flow turned negative in 2026Q2, the rate of cash depletion warrants continued scrutiny, as the cushion may compress further if operating losses persist.

The elimination of borrowings appears to reflect deleveraging rather than strategic restructuring, and it removes near-term refinancing pressure. Because the company now carries no reported debt, its financial risk profile is driven more by operating performance than by leverage, though the absence of debt does not offset ongoing losses.

The stable goodwill balance implies no recent acquisition-driven write-up, though its size relative to a shrinking equity base means a future impairment would be a material distortion worth monitoring. The declining PP&E suggests limited reinvestment in physical capacity, which supports the asset-light characterization but may also signal constrained growth investment.